Author: [email protected]

Release – Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Posted on by [email protected]

May 4, 2026

  • Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases.
  • China innovation engine provides cost-efficient vehicle for discovery and early-stage development of targeted protein degraders and degrader-antibody conjugates.
  • Strengthened leadership team in U.S., coupled with China operating presence to support future global growth.

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) — Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, today announced the closing of its acquisition of Cullgen Inc. (Cullgen), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies, in an all-stock transaction valued at approximately $300 million.

Following the closing of the acquisition, Cullgen became a wholly owned subsidiary of Gyre, and the former Chief Executive Officer of Cullgen, Dr. Ying Luo, was appointed President and Chief Executive Officer and as a member of the Gyre Board of Directors. Ping Zhang will continue at Gyre as Chairman of the Board of Directors. The new combined entity will continue to be listed on the Nasdaq Capital Market under the ticker “GYRE”.

Dr. Luo, President and Chief Executive Officer of Gyre, commented, “We are eager to move forward as a U.S.- and China-based fully integrated biopharmaceutical company. Through this combination, we have created an entity that not only offers a commercial-stage product with ETUARY®, on the market in China for the treatment of lung fibrosis, but also a full-spectrum pipeline of products from discovery to Phase 3, primarily focused on fibrosis and inflammatory diseases. This includes our lead product candidate, F351 (hydronidone) for the treatment of chronic hepatitis B (CHB)-induced liver fibrosis, as well as a strong preclinical and clinical pipeline, including TPDs and DACs.”

Mr. Zhang, Chairman of Gyre, commented, “This combination occurs at an exciting time for Gyre as we recently received priority review status from the Center for Drug Evaluation of China’s National Medical Products Administration for the F351 NDA in March. We are also exploring the expansion of F351’s development in ex-China territories including the U.S. In addition, we have completed enrollment in our 52-week Phase 3 ETUARY® trial for pneumoconiosis, and have also enrolled the first patient in a Phase 3 study evaluating ETUARY® in a new indication: radiation-induced lung injury with or without immune checkpoint inhibitor-related pneumonitis, further strengthening our late-stage inflammatory portfolio. Additionally, we believe the innovative discovery engine that has produced several promising degraders and DACs acquired from Cullgen strengthens our asset portfolio and provides long-term value to Gyre.”

About Gyre Pharmaceuticals

Gyre Pharmaceuticals Co., Ltd., a subsidiary of Gyre Therapeutics, Inc. (“Gyre Pharmaceuticals”), is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY® (pirfenidone capsule), was the first approved treatment for IPF in the People’s Republic of China (PRC) in 2011 and has maintained a prominent market share over the past several years. In addition, Gyre Pharmaceuticals’ pipeline includes F351 (hydronidone), a structural analogue of pirfenidone, which demonstrated statistically significant fibrosis regression after 52 weeks of treatment in a pivotal Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC. F351 received Breakthrough Therapy designation by the CDE of the NMPA in March 2021. Gyre Pharmaceuticals is also developing treatments for PD, RILI with or without immune-related pneumonitis, COPD, PAH and ALF/ACLF. As of December 31, 2025, Gyre Therapeutics owns a 69.7% equity interest in Gyre Pharmaceuticals.

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of F351 for liver fibrosis including MASH in the U.S., and, with its recent acquisition, now has a portfolio of highly selective targeted protein degrader product candidates designed to potently and efficiently eliminate therapeutically relevant proteins in patients, as well as preclinical programs including next-generation degrader-antibody conjugates.

In the PRC, Gyre Therapeutics is advancing a broad pipeline through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528.

Advisory and Legal Counsel

Moelis & Company LLC is acting as financial advisor to the special committee to Gyre’s Board of Directors, and Gyre’s legal counsel is Gibson, Dunn & Crutcher LLP.

Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. is serving as legal counsel to Cullgen.

Release – ISG to Ring Nasdaq Closing Bell

Posted on by [email protected]

May 4, 2026

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, will ring the closing bell at the Nasdaq MarketSite in New York’s Times Square tomorrow to mark the 20th anniversary of the firm’s founding in 2006.

ISG shares were first listed on Nasdaq on February 1, 2008, under the ticker symbol III.

“From our founding in 2006, with no revenues and no payroll, we have grown to become a market-leading, AI-centered technology research and advisory firm,” said Michael P. Connors, chairman and CEO of ISG, who will ring the closing bell. “We now have 1,500 professionals in 20 countries helping more than 900 blue-chip clients embrace one of the most significant technology shifts in decades – leveraging AI for operational excellence and faster growth.”

As an independent advisor to leading global enterprises, ISG influences more than $200 billion of client technology spend each year. In 2025, ISG generated nearly $250 million in revenue and saw its share price rise 78 percent, earning the firm a spot among the top 8 percent of Nasdaq-listed technology companies under $1 billion in market cap.

“ISG is always pivoting to the next,” Connors said. “Over the years, we have expanded our capabilities through a series of acquisitions—15 in all—while growing our business organically through continuous innovation and service excellence.”

Joining in the ceremony are 60 ISG colleagues, including 22 employees with more than 20 years of service, along with family members and honored guests.

“I want to thank everyone who has been a part of our growth,” he said. “Our first 20 years have been an extraordinary journey, and the future is even more exciting. We remain committed to helping clients achieve meaningful business success and to creating long-term value for our shareholders.”

The Nasdaq closing bell ceremony will be webcast live tomorrow starting at 3:45 p.m., U.S. Eastern Time, on the Nasdaq site, Facebook Live and X.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Source: Information Services Group, Inc.

Bitcoin Clears $80,000 for the First Time Since January — Is the Recovery Finally Real?

Posted on by [email protected]

Bitcoin broke through the $80,000 barrier early Monday morning, touching an intraday high of $80,529 during Asian trading hours — its highest price since January 31, 2026. The move snapped a three-month ceiling that had resisted four separate recovery attempts and sent shockwaves through the short-seller community.

The catalyst wasn’t purely crypto-native. Over the weekend, President Trump announced “Project Freedom,” a U.S. military operation to escort stranded commercial vessels through the Strait of Hormuz amid ongoing U.S.-Iran tensions. The announcement, combined with signals of progress on Iran’s 14-point peace proposal, sent Brent crude retreating from a four-year high near $126 to around $107 a barrel. Risk appetite returned swiftly across global markets — and Bitcoin was a primary beneficiary.

Short Sellers Got Crushed

The $80K breach triggered a short squeeze that market participants had been bracing for. Approximately $303 million in Bitcoin short positions were liquidated within 24 hours, with $108 million of those forced out in a single hour as BTC held above the key level. Traders had been aggressively positioned against this break — and when the wall cracked, forced buybacks only amplified the move higher.

More Than a Price Level

The $80,000 threshold carries structural weight beyond its psychological significance. By pushing past $80K, Bitcoin also reclaimed its bull market support band — a moving average zone traders use to determine whether the broader trend is bullish or bearish — for the first time since November 2025. The previous four recovery attempts since the November decline each failed to accomplish this.

Bitcoin had spent the first quarter of 2026 largely trapped below $75,000, falling as low as $62,000 in February before a steady April recovery added roughly 14% month-over-month. Bitcoin is now up over 17% in the past month, with Ethereum gaining over 13% during the same period.

Institutional Demand Has Been Building Quietly

While retail sentiment has been largely absent, institutional buyers have been accumulating steadily. Spot Bitcoin ETFs attracted $630 million in inflows in a single session last week, signaling strong conviction at these price levels. Bitcoin held on exchanges has simultaneously fallen to a seven-year low — a dynamic that historically precedes supply-driven price appreciation.

What Comes Next

The immediate technical picture points to a cluster of resistance between $82,000 and $84,500. A sustained move above $82,000 — roughly where Bitcoin’s 200-day moving average sits — would mark the first confirmed trend reversal signal of the year and could force remaining short sellers to cover at higher prices, further accelerating the move.

Prediction market participants currently give Bitcoin a 47% chance of reaching $85,000 by month-end, with only 21% odds of clearing $90,000 in May. The base case has BTC consolidating in the $78,000–$83,500 range while the market digests the breakout.

Still, the structural shift is notable. Three months of failed attempts, a geopolitical tailwind, a short squeeze, and a reclaimed technical level — for the first time in 2026, Bitcoin bulls have something concrete to point to. Whether this move holds will depend heavily on continued ETF inflows, macro stability, and whether spot demand catches up with the futures-driven April rally.

The $80,000 level has flipped from ceiling to battleground. The next few weeks will determine which side wins.

Star Equity Holdings, Inc. (STRR) – A Contract and GEE Group Comments

Posted on by [email protected]


Monday, May 04, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Contract.  Star Equity Holdings’ wholly owned subsidiary,  KBS Builders, Inc. (“KBS”), signed a $4.2  million contract to manufacture a multifamily housing project in  New Hampshire, further strengthening Star Equity’s growing footprint across the  New England region. KBS’s selection reflects a proven track record of executing complex projects on time and on budget, in our view.

Project. The $4.2  million contract covers the manufacturing of 36 modules for the construction of six 2-unit buildings totaling 26,088 square feet as part of a residential assisted living facility in New  Hampshire. The project is designed to achieve net-zero energy efficiency while delivering high-quality housing with shorter construction timelines and enhanced sustainability. Production is expected to commence in May, with delivery to be completed in the third quarter of 2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Resolution Minerals Ltd (RLMLF) – Accelerating Development at the Horse Heaven Critical Minerals Project

Posted on by [email protected]


Monday, May 04, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Exploration Momentum. Resolution Minerals continues to demonstrate strong exploration results across its Horse Heaven Project, confirming a large-scale, multi-commodity system. High-grade antimony at Antimony Ridge and extensive gold mineralization at Golden Gate highlight the project’s scale, with drilling confirming continuous mineralization that remains open in multiple directions. A major 13,700-meter Phase 2 drilling program is expected to commence this week to further define resource potential and support a maiden Mineral Resource Estimate targeted for Q1 2027.

Advancing Metallurgy and Development Pathways. Resolution is making significant progress in metallurgical testing and project development, particularly with tungsten and antimony processing. Test work has successfully produced high-grade tungsten concentrates and high-purity antimony products, demonstrating viable processing pathways and near-term production potential. Combined with the acquisition of processing infrastructure at Johnson Creek, these developments position the company to advance toward a vertically integrated, U.S.-based critical minerals platform.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

ACCO Brands (ACCO) – A Better Than Anticipated First Quarter

Posted on by [email protected]


Monday, May 04, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. ACCO Brands delivered a solid start to the year, with both sales and adjusted EPS coming in above management’s first-quarter expectations. Results reflected better-than-anticipated comparable sales and EPOS outperforming expectations. The first quarter benefited from favorable foreign exchange and the acquisition of EPOS, including a preliminary bargain purchase gain of $37.6 million.

1Q26 Results. Revenue of $343.7 million exceeded management’s $317-$327 million range and our $320 million estimate. Adjusted net income was $1.8 million, or $0.02/sh, better than the expected adjusted loss range of $0.06-0.03 per share. We had projected an adjusted loss of $6.7 million, or a loss of $0.07/sh.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Belden Bets $1.85 Billion on RUCKUS Networks to Become a Full-Stack IT/OT Powerhouse

Posted on by [email protected]

Belden Inc. (NYSE: BDC) is making its biggest strategic push in years. The St. Louis-based specialty networking solutions provider announced Wednesday it has signed a definitive agreement to acquire RUCKUS Networks from Vistance Networks (Nasdaq: VISN) for approximately $1.85 billion in a debt-financed transaction that fundamentally reshapes what Belden is — and who it competes against.

The deal adds capabilities Belden simply doesn’t have today: enterprise-grade Wi-Fi and switching technology. For a company that has long been the infrastructure layer — the cables, connectors, and passive components behind enterprise and industrial networks — acquiring RUCKUS is a direct move up the stack.

What Belden Is Buying

RUCKUS is not a niche player. The company serves more than 48,000 customers globally with an integrated portfolio spanning Wi-Fi, enterprise switching, and an AI-driven cloud networking platform. Its sweet spots are high-density, mission-critical environments — hospitality, education, and healthcare — exactly the verticals where Belden already has customer relationships and distribution reach.

That overlap is the deal’s core thesis. Belden walks into existing customer accounts and can now offer a complete end-to-end networking solution rather than handing off business to competitors at the active networking layer. The cross-sell opportunity is immediate and doesn’t require building new channels from scratch.

The industrial angle is equally compelling. As manufacturers and industrial operators accelerate the convergence of their IT and OT environments — connecting factory floors to enterprise networks — demand for high-performance wireless and switching in industrial settings is rising sharply. RUCKUS gives Belden a proven platform to chase that opportunity.

The Financial Case

At approximately 13x projected 2026 adjusted EBITDA, Belden is paying a growth multiple, but the numbers justify the premium. RUCKUS comes in with high-single-digit revenue growth, gross margins above 60%, and adjusted EBITDA margins above 20% — all meaningfully better than Belden’s current profile. The transaction is expected to be immediately accretive to adjusted earnings per share and expand both gross and EBITDA margins in the first full year of ownership.

The combined adjusted EBITDA base is projected at approximately $650 million, which gives Belden a meaningful cash generation engine to attack the debt load. J.P. Morgan has provided fully committed debt financing, and Belden expects to bring net leverage below 3.0x within the first full year post-close, targeting approximately 1.5x by 2029. Share repurchases will be paused until leverage is closer to that long-term target — a responsible trade-off given the size of the bet.

The Bigger Picture

This acquisition is Belden making a definitive statement about what it wants to be. The company has spent years positioning around industrial and enterprise connectivity, but selling passive networking infrastructure in a world moving toward software-defined, cloud-managed networking was increasingly a commodity play. RUCKUS changes that equation.

Bringing an AI-driven cloud networking platform under the Belden umbrella alongside established hardware capabilities creates a more defensible, higher-value business. Customers increasingly want fewer vendors and more complete solutions — Belden is positioning itself to be that vendor.

Both boards have approved the transaction. Close is expected in the second half of 2026, pending regulatory approvals.

ARCHIMED to Take Esperion Therapeutics Private in Deal Valued at Up to $1.1 Billion

Posted on by [email protected]

Esperion Therapeutics (Nasdaq: ESPR), the Ann Arbor-based commercial-stage biopharmaceutical company behind a growing portfolio of cardiometabolic therapies, is set to leave public markets after striking a definitive acquisition agreement with ARCHIMED, a Europe-headquartered healthcare-focused private equity firm with €9 billion in assets under management.

Under the terms of the deal announced May 1, 2026, Esperion shareholders will receive $3.16 per share in cash at closing — a 58% premium to the company’s closing share price on April 30 — along with one non-tradeable contingent value right (CVR) that entitles holders to participate in up to $100 million in additional milestone payments tied to future commercial performance. The total equity value of the transaction reaches approximately $1.1 billion on a fully diluted basis, assuming full achievement of those milestones.

The CVR Structure: Upside With Conditions

The contingent payment component is split into two tranches. The first is tied to annual U.S. net sales of bempedoic acid-containing products — primarily NEXLETOL and NEXLIZET — in calendar year 2027. Shareholders can receive up to $40 million in aggregate if those products surpass $350 million in annual sales, with a pro-rated payout if sales fall between $300 million and $350 million.

The second tranche is tied to ENBUMYST, Esperion’s bumetanide-based therapy, and pays out $60 million in aggregate if annual U.S. net sales hit or exceed $160 million in any single calendar year through December 31, 2030.

This CVR structure places meaningful commercial risk on post-close performance, particularly for ENBUMYST, which is the earlier-stage product of the two. Investors accepting the deal should weigh the probability of those sales thresholds being met before banking on the full $1.1 billion figure.

Why This Deal Makes Strategic Sense

Cardiovascular disease remains the leading cause of death globally, and the market for non-statin LDL-C lowering therapies has been steadily expanding. Esperion’s NEXLETOL and NEXLIZET have established commercial infrastructure in the U.S. and regulatory approvals in more than 40 countries, giving ARCHIMED a platform with real geographic reach and an active pipeline.

ARCHIMED’s exclusive focus on healthcare industries and its international network across Europe, North America, and Asia positions it to potentially accelerate Esperion’s international commercial strategy — something that can be difficult to execute efficiently inside a small-cap public company under the constraints of quarterly earnings pressure.

Deal Mechanics and Timeline

Debt financing for the acquisition is being provided by Pharmakon Advisors, LP, a specialized life sciences lender that has deployed up to $11 billion across 73 investments. The transaction carries no financing condition, which reduces deal risk meaningfully.

Esperion’s Board of Directors unanimously approved the deal and is recommending shareholder approval. The transaction is expected to close in the third quarter of 2026, pending shareholder vote and regulatory clearance. Moelis & Company is advising ARCHIMED, while Centerview Partners is advising Esperion.

Once the deal closes, Esperion will be delisted from Nasdaq and operate as a privately held company — removing a once-public cardiometabolic pure-play from the small-cap biotech universe.

Titan International (TWI) – A Solid Start to the Year

Posted on by [email protected]


Friday, May 01, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Titan’s first quarter 2026 results came in at the high end of management’s expectations and above our projections, partly driven by positive forex. Titan achieved this performance against a macro backdrop that continues to be very dynamic. Once again, EMC was the star performer with revenue up 11.3% year-over-year and gross margin up 90 basis points. With a diversified portfolio of products, strategically positioned global plants, and a one-stop shop distribution channel, we believe Titan is well-positioned for today’s dynamic operating environment.

1Q26 Results. Revenue of $505 million was up 2.9% y-o-y and exceeded our $495 million projection. The revenue increase was driven by forex gains, which added approximately 3.7% to net sales growth. Gross margin improved to 14.1% from 14.0%. Adjusted EBITDA totaled $31.4 million, up from $30.8 million a year ago and our $26 million estimate. Titan reported adjusted EPS of breakeven versus adjusted EPS of $0.01 last year and our $0.03 estimate.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN (NNBR) – CARES Act Refund

Posted on by [email protected]


Friday, May 01, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Refund. NN announced that the Company has been notified that its CARES Act refund has been processed for payment. The refund is in excess of $10 million. This refund has been a long time in coming, but will help the Company in its growth efforts, in our view.

Growth Opportunity. The tax refund will more than offset the $10 million the Company borrowed in 1Q26 to fund certain growth areas with both capital equipment and working capital. While it is too soon to say which path the Company will follow, the tax refund could enable to further boost the abundant growth opportunities through additional investment or repay the 1Q26 borrowing.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Fleet Expansion Strengthens Long-Term Earnings Visibility

Posted on by [email protected]


Friday, May 01, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Euroseas expands its fleet. The company has ordered four additional feeder containerships, including two high-reefer vessels and two standard feeder ships, bringing its total newbuild program to ten vessels with a combined cost of about $500 million. Upon completion of the current newbuild program, Euroseas will operate 31 vessels with a total capacity of 93,834 twenty-foot equivalent units (TEU). The expansion reflects confidence in the feeder market and a deliberate focus on higher value cargo segments, particularly refrigerated goods, while also incorporating optionality for further fleet growth.

Strong earnings visibility. With a contracted revenue backlog of roughly $650 million and charter coverage extending beyond 2028, the company has secured a high level of earnings visibility. The current fleet is largely employed under time charter agreements at favorable rates, reducing exposure to market volatility and supporting stable cash flow generation to fund ongoing expansion.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Cadrenal Therapeutics (CVKD) – Preliminary Design For CAD-1005 Phase 3 In HIT Announced

Posted on by [email protected]


Friday, May 01, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 3 Design Announced. Cadrenal held an end-of-Phase-2 meeting with the FDA to discuss the results of the CAD-1005 trial and receive guidance for the design of Phase 3. Following the receipt of the Meeting Minutes, the preliminary design for Phase 3 in HIT (Heparin-Induced Thrombocytopenia) has been announced. The trial is expected to begin in late FY2026 to early FY2027, with an NDA possible in FY2019.

HIT Is A Serious Condition. HIT is a potentially life-threatening immune reaction to heparin, an anticoagulant currently used in an estimated 12 million cardiac surgeries. HIT affects up to 5% of these patients, forming immune complexes that can activate platelets and cause excessive clotting. About 50% experience thrombosis, as well as embolisms, skin necrosis, and other cardiac events that can be fatal. CAD-1005 is a selective inhibitor of the 12-LOX immune pathway that causes HIT. This contrasts with other drugs that control symptoms and secondary morbidities following the immune response.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Banner Bank Moves to Absorb Bank of the Pacific in All-Stock Deal, Combined Entity to Hit $18 Billion in Assets

Posted on by [email protected]

Banner Corporation (Nasdaq: BANR), the Walla Walla, Washington-based holding company for Banner Bank, has reached a definitive agreement to acquire Pacific Financial Corporation (OTCQX: PFLC), the parent of Bank of the Pacific, in an all-stock transaction valued at approximately $177 million. The deal, announced jointly by both companies, would push the combined institution to roughly $18 billion in total assets upon closing.

Deal Terms

Pacific Financial shareholders will receive 0.2633 shares of Banner common stock for each share of Pacific Financial they hold. Based on Banner’s April 29 closing price of $66.25, that translates to an implied value of $17.44 per Pacific Financial share. Following the close, Pacific Financial shareholders are expected to own approximately 7% of the combined company, with Banner’s existing shareholders holding the remaining 93%.

Banner has signaled the transaction is expected to be immediately accretive to 2027 earnings per share, excluding one-time transaction costs — a metric that will matter to BANR investors assessing dilution risk from the share issuance.

What Banner Is Getting

Bank of the Pacific brings 55 years of community banking history to the table. As of March 31, 2026, the Aberdeen, Washington-based institution carried $1.29 billion in assets, a $762 million loan portfolio, and — arguably most attractive to Banner — a $1.14 billion low-cost deposit base spread across 18 branches and offices in Western Washington and Northern Oregon.

That deposit quality is the real story here. In a rate environment where core deposit franchises command serious strategic value, Bank of the Pacific’s funding profile is precisely the kind of asset larger regional banks are hunting for. Low-cost deposits improve net interest margins and reduce reliance on more expensive wholesale funding — a meaningful operational benefit for Banner as it scales.

Geographic Logic

Banner Bank already operates across Washington, Oregon, Idaho, and California, giving it strong Pacific Northwest coverage. The Pacific Financial acquisition deepens penetration specifically in Western Washington and Western Oregon — coastal and rural markets where community banking relationships tend to be sticky and competition from money-center banks is less intense.

For Bank of the Pacific customers, the combination brings access to broader product offerings, higher commercial lending limits, and expanded branch infrastructure — the typical value proposition in community bank consolidation that tends to hold up in practice.

Leadership Continuity

One notable element of the deal structure: Denise Portmann, Bank of the Pacific’s President and CEO, is expected to join the Banner Bank executive team following close. Retaining acquired leadership, particularly in relationship-driven community banking, is a meaningful risk mitigant. It signals cultural alignment between the two institutions and helps protect client relationships during the transition period.

Timeline and Advisors

Both boards unanimously approved the transaction. Closing is targeted for the third quarter of 2026, pending Pacific Financial shareholder approval and regulatory clearance. Piper Sandler advised Pacific Financial, with Miller Nash LLP as legal counsel. BofA Securities advised Banner, with Ballard Spahr LLP handling legal.

This transaction is a clean example of the community bank consolidation trend that has been accelerating across the U.S. as smaller institutions face mounting pressure from technology costs, regulatory burden, and margin compression — dynamics that continue to favor scale.